Gynecologic Oncology | Specialty

Antiangiogenic Agents in Ovarian Cancer

November 26th 2014

Treatment Options in Ovarian Cancer

November 26th 2014

Chemotherapy Regimens for Ovarian Cancer

November 26th 2014

Goal of Surgery in Ovarian Cancer

November 26th 2014

Cytoreductive Surgery for Ovarian Cancer

November 26th 2014

Neoadjuvant Chemotherapy for Ovarian Cancer

November 26th 2014

Timing of Oophorectomy in Ovarian Cancer

November 26th 2014

Prophylactic Oophorectomy for Reducing Ovarian Cancer Risk

November 26th 2014

Universal Screening for BRCA1 and BRCA2 Mutations

November 26th 2014

Cediranib Combined With Chemotherapy Improves PFS in Advanced Cervical Cancer

September 28th 2014

Cediranib improved response rate and median PFS when added to conventional chemotherapy in a phase II study of patients with relapsed or metastatic cervical cancer.

DHEA Therapy Offers Relief From Vaginal Symptoms in Cancer Survivors

August 21st 2014

A randomized multicenter trial examining the efficacy of adding dehydroepiandosterone (DHEA) to a vaginal bioadhesive moisturizer in postmenopausal survivors of breast or gynecologic cancer has found that daily rather than as-needed use of such a moisturizer significantly relieves symptoms of vaginal atrophy in these women.

FDA Approves Bevacizumab for Advanced Cervical Cancer

August 14th 2014

The FDA has approved bevacizumab in combination with paclitaxel and cisplatin or paclitaxel and topotecan as a treatment for patients with persistent, recurrent, or metastatic cervical cancer.

Immunotherapy Branches Out

July 18th 2014

Immunotherapy agents are delivering impressive results in a broad range of tumor types, reinforcing the excitement in research and investment circles for anticancer strategies that actively harness the immune system

FDA Grants Priority Review to Bevacizumab in Advanced Cervical Cancer

July 15th 2014

The FDA has assigned a priority review designation to bevacizumab (Avastin) plus chemotherapy as a treatment for patients with persistent, recurrent, or metastatic cervical cancer.

Dr. Monk on Bevacizumab in Recurrent Cervical Cancer

July 14th 2014

Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the utility of bevacizumab in recurrent cervical cancer.

HPV-Targeting Immunotherapy Shows Early Promise in Cervical Cancer

June 2nd 2014

Two patients with metastatic cervical cancer achieved durable complete responses that have so far lasted from 15 to 22 months through an adoptive T-cell therapy (ACT) targeting the human papillomavirus (HPV) in a study that researchers say supports the concept that the experimental immunotherapy approach may be beneficial in a variety of tumor types.

Study Suggests More Than Two-Thirds of Healthy Americans Are Infected with Human Papilloma Viruses

May 28th 2014

Only a Few of More Than 109 Detected Strains Known to Cause Cancer

HPV Test With Genotyping Tops Cervical Cancer Screening Strategies

May 27th 2014

Cervical cancer screening based on identification of human papillomavirus (HPV) strains outperformed primary liquid cytology for detection of high-grade cervical intraepithelial neoplasia (CIN), data from a large cohort study showed.

For Premenopausal Women With ER-Positive Disease, Obesity Is a Major Risk Factor in Breast Cancer Mortality

May 14th 2014

Obesity significantly increases the risk of dying of breast cancer in premenopausal women with ER-positive early disease.

FDA Approves First HPV Test for Primary Cervical Cancer Screening

April 24th 2014

The FDA has approved the cobas HPV Test as a first-line screening tool for cervical cancer in women 25 and older, making it the first-ever approval for a diagnostic alternative to Pap smear.